Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gastrointestinal 1CNS 1

Conditions

Rhabdomyosarcoma 1Osteosarcoma 1Neuroectodermal Tumors, Primitive, Peripheral 1Neuroblastoma 1Hepatoblastoma 1

Interventions

Isotretinoin 3imetelstat 2Peripheral Blood Stem Cell Transplantation 2Cyclophosphamide 2thymoglobulin 1pazopanib 1naxitamab 1lorukafusp alfa 1liposomal doxorubicin 1keyhole-limpet hemocyanin 1fludarabine phosphate 1fludarabine 1defibrotide 1arginyllysine 1Whole-Body Irradiation 1Whole Body Imaging 1Vincristine 1Vaccines 1Tretinoin 1Topotecan 1Thiotepa 1Therapeutics 1Temozolomide 1Tacrolimus 1Stem Cell Transplantation 1Spermine Synthase 1Specimen Handling 1Radiotherapy 1Radiation 1Pentetic Acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Neuroblastoma × GRN163L peptide × Clear all
NCT02011126 2018-08-07

Imetelstat Sodium in Treating Younger Patients With Relapsed or Refractory Solid Tumors

Children's Oncology Group

Phase 2 Withdrawn
CNSGastrointestinalSarcoma

Neuroblastoma, Rhabdomyosarcoma, Osteosarcoma, Hepatoblastoma, Neuroectodermal Tumors, Primitive, Peripheral

Data powered by HemOnc (CC BY 4.0) Colophon âš¡